



Vanessa Kennedy

Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Bone Marrow Transplant**

780 Welch Road CJ250B

Stanford, CA 94305

Tel (650) 723-0822 Fax (650) 725-7850

Bio

BIO

Dr. Kennedy is a board-certified hematologist and medical oncologist who specializes in the treatment of myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis (MF). She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine.

Dr. Kennedy's research focuses on the use of clinical informatics and bioinformatics in understanding cancer biology and improving patient outcomes. She is also actively involved in interventional clinical trials. Her work has been supported by grant funding from the American Society of Clinical Oncology, the American Society of Hematology, and the Chan-Zuckerberg Foundation.

CLINICAL FOCUS

- Hematology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

HONORS AND AWARDS

- Physician-Scientist Fellow, Chan-Zuckerberg Institute (2021 - 2023)
- Editorial Fellow, Journal of Clinical Oncology - Clinical Cancer Informatics (2022 - 2023)
- Young Investigator Award, American Society of Clinical Oncology (2022)
- Abstract Achievement Award, American Society of Hematology (2020)
- Rachel Perline Award, UCSF (2020)
- HONORS Award, American Society of Hematology (2018)
- Abstract Achievement Award, American Society of Hematology (2015)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2023)

- Board Certification, American Board of Internal Medicine , Medical Oncology (2023)
- Board Certification: Hematology, American Board of Internal Medicine (2022)
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2022) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2019)
- Residency: Stanford University Internal Medicine Residency (2019) CA
- Medical Education: Vanderbilt University School of Medicine (2016) TN

Research & Scholarship

CLINICAL TRIALS

- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203), Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS, Not Recruiting
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT, Not Specified

Publications

PUBLICATIONS

- **Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.** *Blood*
Kennedy, V. E., Peretz, C. A., Walia, A., Chyla, B., Sun, Y., Hill, J. E., Tran, E., Koh, A. D., Ferng, T. T., Pintar, S., Jones, M., Popescu, B., Lomeli, et al
2026
- **CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.** *Nature medicine*
DiPersio, J. F., Koehne, G., Shah, N. N., Bernard, L., Suh, H. C., Koura, D., Tamari, R., Mushtaq, M. U., Maakaron, J., Rimando, J., Kennedy, V. E., Patel, S. S., Hudson, et al
2026
- **Multomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.** *European journal of haematology*
Kennedy, V. E., Peretz, C. A., Koh, A., Tran, E., Dhingra, D., Gulati, S., Sciambi, A., Sala-Torra, O., Beppu, L., Radich, J. P., Smith, C. C.
2026
- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Clonally Distinct FLT3-TKD Mutations in Host and Donor-Derived AML After Double Cord Blood Transplant: A Case Report.** *EJHaem*
Rojansky, R. B., Law, L. Y., Zhang, B. M., Kennedy, V. E.
2026; 7: e70292
- **Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study.** *Journal of geriatric oncology*
Kennedy, V. E., Block, A., Young, C., Nimke, D., Kardel, P., Pednekar, P.
2026; 17 (4): 102959
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al

2026

- **Inclusion as innovation: broadening trial criteria in AML.** *Blood*
Kennedy, V. E., Muffly, L.
2026; 147 (6): 604-605
- **Inclusion as innovation: broadening trial criteria in AML** *BLOOD*
Kennedy, V. E., Muffly, L.
2026; 147 (6): 604-605
- **Relationship between Social Drivers of Health and Clinician Adherence to Late Effects Screening Among Allogeneic HCT Survivors in the United States**
Taylor, A. O., Hong, S., Jones, S., Ng, K., Gooley, T. A., Bhatt, N., Hellewell, E. M., D Sung, A., Ahmed, N., Morey, C., Fitzmaurice, S., Kennedy, V. E., Lauer, et al
ELSEVIER SCIENCE INC.2026: S24-S25
- **Epixtract: An Artificial Intelligence-Driven Tool to Optimize Data Abstraction for CIBMTR Reporting**
Scheck, A., Pua, E., Yang, E., Lowsky, R., Miklos, D. B., Zeng, J., Kennedy, V. E.
ELSEVIER SCIENCE INC.2026: S96
- **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
ELSEVIER SCIENCE INC.2026
- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
ELSEVIER SCIENCE INC.2026
- **High Molecular Weight Isoforms of Thymic Stromal Lymphopoietin Correlate with Presence and Severity of Acute Graft Versus Host Disease**
Shiraz, P., Louloudis, I., Liliental, J. A., Muffly, L. S., Kennedy, V. E., Patel, S., Negrin, R. S., Lowsky, R., Arai, S., Johnston, L., Rezvani, A. R., Weng, W., Bharadwaj, et al
ELSEVIER SCIENCE INC.2026: S46-S47
- **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucl and Brexucabtagene Autoleucl for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al
ELSEVIER SCIENCE INC.2026: S27
- **Holistic evaluation of large language models for medical tasks with MedHELM.** *Nature medicine*
Bedi, S., Cui, H., Fuentes, M., Unell, A., Wornow, M., Banda, J. M., Kotecha, N., Keyes, T., Mai, Y., Oez, M., Qiu, H., Jain, S., Schettini, et al
2026
- **HSPC-like blasts in acute lymphoblastic leukemia: biology and therapeutic opportunities.** *Trends in cancer*
Xu, J., Kennedy, V. A., Ma, C., Sussman, J. H., Bandyopadhyay, S., Chen, C., Teachey, D. T., Tan, K.
2025
- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al
ELSEVIER.2025: 2494-2495
- **Multi-omic single cell sequencing reveals discordant MRD and mechanisms of relapse in pediatric AML**
Peretz, C., Murad, N., Gladden, R., Walia, A., Koh, A., Tran, E., Kennedy, V., Bhise, S., Fan, E., Ries, R., Huang, B., Meshinchi, S., Olshen, et al
ELSEVIER.2025: 348-349
- **Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort.** *Blood cancer journal*

- Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D. M., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
2025; 15 (1): 208
- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**
Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
ELSEVIER.2025: 4159-4160
 - **The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission**
Yu, K., Dillon, L., Tettero, J., Gui, G., Al-Ali, R., Grunwald, M., Krakow, E., Griffiths, E., Gomez-Arteaga, A., Vedula, R., Solh, M., Salhotra, A., Bejanyan, et al
ELSEVIER.2025: 455-456
 - **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
ELSEVIER.2025: 2525-2526
 - **Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease**
Shiraz, P., Louloudis, L., Lilliental, J., Patel, S., Jensen, A., Fonseca, S., Le, K., Diallo, B., Pavlova, A., Arai, S., Negrin, R., Rezvani, A., Johnston, et al
ELSEVIER.2025: 586-587
 - **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al
ELSEVIER.2025: 514-515
 - **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
 - **Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data. *Leukemia & lymphoma***
Kennedy, V. E., Touya, M., Spalding, J., Young, C., Cao, L. F., Nimke, D., Block, A., Pednekar, P.
2025: 1-11
 - **Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). *JCO precision oncology***
Koehne, G., Mushtaq, M. U., Muffly, L. S., Menes, M., Azzi, J., Bernard, L., Cooper, B., Kennedy, V., Koura, D., Maakaron, J., Magenau, J., McClune, B., Patel, et al
2025; 9: e2500556
 - **Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. *Nature reviews. Clinical oncology***
Glaviano, A., Weisberg, E., Lam, H. Y., Tan, D. J., Innes, A. J., Ge, Y., Lai, C. E., Stock, W., Glytsou, C., Smit, L., Yoshida, T., Zhang, T. Y., Kennedy, et al
2025
 - **Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT. *Transplantation and cellular therapy***
Espinoza-Gutierrez, M. R., Collins, J., Kennedy, V., Randall, J., Su, C. T., Banerjee, R., Wuliji, N., Odstrcil-Bobillo, S., Amonoo, H. L., Wood, W. A., Hamilton, B., Sung, A., Lee, et al
2025
 - **Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT. *Transplantation and cellular therapy***
Kennedy, V. E., Ahmed, N., Artz, A., Bhatt, N. S., Custatis, R., Espinoza-Gutierrez, M. R., Farhan, S., Ferguson, R. J., Hamilton, B., Katz, H., Kelly, D. L., Knight, J. M., Lee, et al

2025

- **Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.** *Transplantation and cellular therapy*
Banerjee, R., Amonoo, H. L., Barata, A., Bhatt, N. S., Espinoza-Gutierrez, M. R., Jayani-Kosarzycki, R. V., Katz, H., Kennedy, V. E., Nawas, M., Steineck, A., Wanjiku, C., Costanzo, E., Cusatis, et al
2025
- **Assessing Physical Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT.** *Transplantation and cellular therapy*
Farhan, S., Kennedy, V. E., Espinoza-Gutierrez, M. R., Lust, H., Bobillo, M. S., Lin, A. Y., Olin, R. L., Lin, R. J., Rentscher, K. E., Taylor, M. R., Mohanraj, L., Wood, W. A., Murthy, et al
2025
- **Single Nucleotide Polymorphism (SNP) and Antibody-based Cell Sorting (SNACS): A tool for demultiplexing single-cell DNA sequencing data.** *Bioinformatics (Oxford, England)*
Kennedy, V. E., Roy, R., Peretz, C. A., Koh, A., Tran, E., Smith, C. C., Olshen, A. B.
2025
- **Real-world adherence and tolerability of FLT3 inhibitors as post-allogeneic transplant maintenance therapy in older adults with AML: A Medicare claims data cohort study**
Kennedy, V., Block, A., Young, C., Kardel, P., Shah, S.
LIPPINCOTT WILLIAMS & WILKINS.2025: e18505
- **Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission**
Elias, S., Brown, S., Eagini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025
- **The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a realworld study using large-scale electronic health record data.** *Haematologica*
Schwede, M., Rodriguez, G., Kennedy, V. E., Henry, S., Wood, D., Mannis, G. N., Majeti, R., Chen, J. H., Bendavid, E., Zhang, T. Y.
2025
- **CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition**
Ferng, T. T., Pintar, S. M., Kennedy, V. E., Kabir, S., Ili, T., Steri, V., Phojanakong, P., Hubner, J., Morales, C. E., Rivera, J. M., Logan, A. C., Braun, B., Stieglitz, et al
ELSEVIER.2024: 723-724
- **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
- **Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)**
Homsy, S., Seki, T., Nguyen, H., Shimura, A., Gorantla, N., Phuong, N., Ghalehsari, N., Velayati, A., Jeyakumar, N., Hamilton, M. P., Kennedy, V. E., Mikkilineni, L., Bharadwaj, et al
ELSEVIER.2024: 7134-7135
- **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffly, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680

- **Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States**
Lee, C. J., Hellewell, E. M., Ng, K., Gooley, T., Sung, A. D., Taylor, A. O., Hong, S., Ahmed, N., Morey, C., Fitzmaurice, S., Kennedy, V. E., Lauer, M., Trunk, et al
ELSEVIER.2024: 2170-2172
- **Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States**
Bhatt, N. S., Hellewell, E. M., Ng, K., Gooley, T., Sung, A. D., Taylor, A. O., Hong, S., Ahmed, N., Morey, C., Fitzmaurice, S., Kennedy, V. E., Lauer, M., Trunk, et al
ELSEVIER.2024: 4921-4923
- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance**
Jones, M. F., Peretz, C. A. C., Kennedy, V. E., Tran, E., Koh, A., Kotini, A., Olszewska, M., Papapetrou, E., Smith, C. C.
ELSEVIER.2024: 1379-1380
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucl Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
- **Multomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia. *Nature communications***
Peretz, C. A., Kennedy, V. E., Wallia, A., Delley, C. L., Koh, A., Tran, E., Clark, I. C., Hayford, C. E., D'Amato, C., Xue, Y., Fontanez, K. M., May-Zhang, A. A., Smithers, et al
2024; 15 (1): 8191
- **Hybrid allogeneic bone marrow transplant rescue approach after acute myelogenous leukaemia relapse in a high-risk patient. *British journal of haematology***
Villar-Prados, A., Kennedy, V. E., Meyer, E. H.
2024
- **Treatment Adherence and Persistence of FLT3 Inhibitors as Post-Allogenic Hematopoietic Cell Transplant Maintenance Therapy in Patients With Acute Myeloid Leukemia in the United States: A Cohort Study Using Administrative Claims Data**
Kennedy, V. E., Touya, M., Spalding, J., Young, C., Cao, L., Nimke, D., Block, A., Pednekar, P.
CIG MEDIA GROUP, LP.2024: S296-S297
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. *Blood***
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Monoclonal Gammopathy of Anemic Significance? Resolution of Pure Red Cell Aplasia With Daratumumab-Based Therapy. *The American journal of medicine***
Khan, O., Prakash, S., Chung, A., Wong, S. W., Kennedy, V. E.

2024; 137 (7): 589-591

- **Advancing Readership Needs of the Clinical Cancer Informatics Community.** *JCO clinical cancer informatics*
Kennedy, V. E., Bates, B. A., Rooney, M. K.
2024; 8: e2400024
- **Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.** *Allergy*
Niedoszytko, M., Gorska, A., Brockow, K., Bonadonna, P., Lange, M., Kluin-Nelemans, H., Oude-Elberink, H., Sabato, V., Shoumariyeh, K., von Bubnoff, D., Müller, S., Illerhaus, A., Doubek, et al
2024
- **Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab.** *Transplantation and cellular therapy*
Kennedy, V. E., Sahaf, B., Wu, F., Ehlinger, Z. J., Arai, S., Miklos, D. B.
2024
- **CORAL: Expert-Curated Oncology Reports to Advance Language Model Inference** *New England Journal of Medicine - Artificial Intelligence*
Sushil, M., Kennedy, V. E., Mandair, D., Miao, B. K., Zack, T., Butte, A.
2024
- **LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.** *Haematologica*
Wintering, A., Hecht, A., Meyer, J., Wong, E. B., Hübner, J., Abelson, S., Feldman, K., Kennedy, V. E., Peretz, C. A., French, D. L., Maguire, J. A., Jobaliya, C., Vasquez, et al
2023
- **The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.** *American journal of hematology*
Joshi, S. K., Pittsenbarger, J., Kennedy, V. E., Peretz, C. A., Perl, A. E., Smith, C. C., Tyner, J. W., Druker, B. J., Traer, E.
2023
- **Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.** *Leukemia & lymphoma*
Gaut, D., Oliai, C., Boiarsky, J., Zhang, S., Salhotra, A., Azenkot, T., Kennedy, V. E., Khanna, V., Olmedo Gutierrez, K., Shukla, N., Moskoff, B., Park, G., Afkhami, et al
2023: 1-9
- **Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.** *Current problems in cancer*
Kennedy, V. E., Natsuhara, K., Maringanti, S. A., Shah, N. D., Arora, S., Wolf, J., Martin, T. G., Aras, M. A., Chung, A., Wong, S. W.
2023; 47 (3): 100953
- **Microfluidics-free single-cell genomics with templated emulsification.** *Nature biotechnology*
Clark, I. C., Fontanez, K. M., Meltzer, R. H., Xue, Y., Hayford, C., May-Zhang, A., D'Amato, C., Osman, A., Zhang, J. Q., Hettige, P., Ishibashi, J. S., Delley, C. L., Weisgerber, et al
2023
- **Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry.** *Blood advances*
Kennedy, V. E., Perkins, C., Reiter, A., Jawhar, M., Lubke, J., Kluin-Nelemans, H. C., Shomali, W., Langford, C., Abuel, J., Hermine, O., Niedoszytko, M., Gorska, A., Mital, et al
2022
- **Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma.** *Journal of geriatric oncology*
Kennedy, V. E., Huang, C. Y., Kaplan, L. D., Andreadis, C., Ai, W. Z., Olin, R. L.
2022; 13 (5): 644-647
- **Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.** *Blood advances*
Kambhampati, S., Sheng, Y., Huang, C. Y., Bylsma, S., Lo, M., Kennedy, V., Natsuhara, K., Martin, T., Wolf, J., Shah, N., Wong, S. W.
2022; 6 (7): 2045-2054
- **Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.** *American journal of hematology*
Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., Jonas, B. A., Mittal, V., Logan, A. C., Muffly, L. S., Mannis, G. N.

2022

- **Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.** *British journal of haematology*
On, S., Rath, C. G., Lan, M., Wu, B., Lau, K. M., Cheung, E., Alegria, W., Young, R., Tan, M., Kim, C., Phun, J., Patel, N., Mannis, et al
2022
- **Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.** *Blood advances*
Kennedy, V. E., Wong, C., Huang, C. Y., Kambhampati, S., Wolf, J., Martin, T. G., Shah, N., Wong, S. W.
2021; 5 (23): 5344-5348
- **VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.** *Blood advances*
Kennedy, V. E., Wong, C. C., Hong, J. M., Peng, T., Brondfield, S., Reilly, L. M., Cornett, P., Leavitt, A. D.
2021; 5 (22): 4662-4665
- **Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care.** *The Lancet. Haematology*
Kennedy, V. E., Olin, R. L.
2021; 8 (11): e853-e861
- **Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.** *Cancer*
Kennedy, V. E., Keegan, T. H., Li, Q., Maguire, F. B., Muffly, L. S.
2021
- **Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.** *Transplantation and cellular therapy*
Banerjee, R., Marsal, J., Huang, C. Y., Lo, M., Kambhampati, S., Kennedy, V. E., Arora, S., Wolf, J. L., Martin, T. G., Wong, S. W., Shah, N.
2021; 27 (6): 477.e1-477.e7
- **Strongyloides Hyperinfection After Immunosuppression in an Immigrant From El Salvador A Case for Early Diagnosis and Treatment** *JCR-JOURNAL OF CLINICAL RHEUMATOLOGY*
Hoppenfeld, M., Kennedy, V., Sheth, K., Chang, A., Nelson, J., Fairchild, R.
2021; 27 (4): E128+
- **A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.** *Clinical lymphoma, myeloma & leukemia*
Kennedy, V. E., Ruiz-Cordero, R., Jangam, D., Wen, K. W., Dunavin, N., Ohgami, R. S., Bhargava, P., Ai, W., Fakhri, B.
2021
- **Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.** *Theranostics*
Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., Illerhaus, A., Oude Elberink, H. N., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, et al
2021; 11 (1): 292-303
- **FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.** *Frontiers in oncology*
Kennedy, V. E., Smith, C. C.
2020; 10: 612880
- **Marked Hyperbilirubinemia-Silent No More!** *The American journal of medicine*
Kennedy, V. E., Leavitt, A. D., Cornett, P.
2020; 133 (12): e733-e734
- **Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia.** *JNCI cancer spectrum*
Muffly, L., Maguire, F. B., Li, Q., Kennedy, V., Keegan, T. H.
2020; 4 (4): pkaa025
- **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis**
Jawhar, M., Schwaab, J., Alvarez-Twose, I., Shoumariyeh, K., Naumann, N., Luebke, J., Perkins, C., Munoz-Gonzalez, J. I., Meggendorfer, M., Kennedy, V., Metzgeroth, G., Fabarius, A., Pfeifer, et al
KARGER.2020: 107-8

- **Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.** *Leukemia*
Kluin-Nelemans, H. C., Reiter, A., Illerhaus, A., van Anrooij, B., Hartmann, K., Span, L. F., Gorska, A., Niekoszko, M., Lange, M., Scaffidi, L., Zanotti, R., Bonadonna, P., Perkins, et al
2019
- **Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab**
Kennedy, V. E., Arai, S., Miklos, D. B., Wu, F.
AMER SOC HEMATOLOGY.2019
- **Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type**
Muffly, L. S., Maguire, F., Li, Q., Kennedy, V., Keegan, T. H. M.
AMER SOC HEMATOLOGY.2019
- **Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience** *FRONTIERS IN ONCOLOGY*
Sheth, V., Kennedy, V., de Lavallade, H., Mclornan, D., Potter, V., Engelhardt, B. G., Savani, B., Chinratanalab, W., Goodman, S., Greer, J., Kassim, A., York, S., Kenyon, et al
2019; 9
- **Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience.** *Frontiers in oncology*
Sheth, V., Kennedy, V., de Lavallade, H., Mclornan, D., Potter, V., Engelhardt, B. G., Savani, B., Chinratanalab, W., Goodman, S., Greer, J., Kassim, A., York, S., Kenyon, et al
2019; 9: 623
- **Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions** *EXPERT REVIEW OF HEMATOLOGY*
Kennedy, V. E., Muffly, L. S.
2019; 12 (2): 99-106
- **Assessment of Older Adult Candidates for Allogeneic Hematopoietic Cell Transplantation: Updates and Remaining Questions.** *Expert review of hematology*
Kennedy, V. E., Muffly, L. S.
2019
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
- **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Jawhar, M. n., Schwaab, J. n., Álvarez-Twose, I. n., Shoumariyeh, K. n., Naumann, N. n., Lübke, J. n., Perkins, C. n., Muñoz-González, J. I., Meggendorfer, M. n., Kennedy, V. n., Metzgeroth, G. n., Fabarius, A. n., Pfeifer, et al
2019: JCO1900640
- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.** *The journal of allergy and clinical immunology. In practice*
Valent, P., Oude Elberink, J. N., Gorska, A., Lange, M., Zanotti, R., van Anrooij, B., Bonifacio, M., Bonadonna, P., Gleixner, K. V., Hadzijusufovic, E., Perkins, C., Hartmann, K., Illerhaus, et al
2018
- **Importance of peripheral blood absolute lymphocyte counts (ALC) in predicting transplant outcomes in preparative regimens using anti-thymocyte globulin or alemtuzumab: an international 2 centre experience**

- Sheth, V., Kennedy, V., de Lavallade, H., Mclornan, D., Potter, V., Savani, B., Chinratanalab, W., Engelhardt, B., Goodman, S., Greer, J., Kassim, A., York, S., Kulasekararaj, et al
NATURE PUBLISHING GROUP.2018: 425–26
- **Strongyloides Hyperinfection After Immunosuppression in an Immigrant From El Salvador: A Case for Early Diagnosis and Treatment.** *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*
Hoppenfeld, M. S., Kennedy, V., Sheth, K., Chang, A., Nelson, J., Fairchild, R. M.
2018
 - **Defining the complex phenotype of severe systemic loxoscelism using a large electronic health record cohort** *PLOS ONE*
Robinson, J. R., Kennedy, V. E., Doss, Y., Bastarache, L., Denny, J., Warner, J. L.
2017; 12 (4)
 - **Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.** *Biology of blood and marrow transplantation*
Hamilton, B. K., Rybicki, L., Abounader, D., Adekola, K., Advani, A., Aldoss, I., Bachanova, V., Bashey, A., Brown, S., DeLima, M., Devine, S., Flowers, C. R., Ganguly, et al
2017
 - **Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.** *Journal of hematology & oncology*
Epperla, N. n., Ahn, K. W., Ahmed, S. n., Jagasia, M. n., DiGilio, A. n., Devine, S. M., Jaglowski, S. n., Kennedy, V. n., Rezvani, A. R., Smith, S. M., Sureda, A. n., Fenske, T. S., Kharfan-Dabaja, et al
2017; 10 (1): 117
 - **Optimizing Anti-Thymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplant Based on Recipient Absolute Lymphocyte Count.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Kennedy, V. E., Chen, H. n., Savani, B. N., Greer, J. n., Kassim, A. A., Engelhardt, B. G., Goodman, S. n., Sengsayadeth, S. n., Chinratanalab, W. n., Jagasia, M. n.
2017
 - **Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Kennedy, V. E., Savani, B. N., Greer, J. P., Kassim, A. A., Engelhardt, B. G., Goodman, S. A., Sengsayadeth, S., Chinratanalab, W., Jagasia, M.
2016; 22 (10): 1801-1807
 - **Does adherence to epilepsy quality measures correlate with reduced epilepsy-related adverse hospitalizations? A retrospective experience** *EPILEPSIA*
Ladner, T. R., Morgan, C. D., Pomerantz, D. J., Kennedy, V. E., Azar, N., Haas, K., Lagrange, A., Gallagher, M., Singh, P., Abou-Khalil, B. W., Arain, A. M.
2015; 56 (5): E63-E67
 - **Hyaluronan Contributes to Bronchiolitis Obliterans Syndrome and Stimulates Lung Allograft Rejection through Activation of Innate Immunity** *AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE*
Todd, J. L., Wang, X., Sugimoto, S., Kennedy, V. E., Zhang, H. L., Pavlisko, E. N., Kelly, F. L., Huang, H., Kreisel, D., Palmer, S. M., Gelman, A. E.
2014; 189 (5): 556-566
 - **Bronchoalveolar Lavage as a Tool to Predict, Diagnose and Understand Bronchiolitis Obliterans Syndrome** *AMERICAN JOURNAL OF TRANSPLANTATION*
KENNEDY, V. E., Todd, J. L., Palmer, S. M.
2013; 13 (3): 552-561
 - **Epithelial clara cell injury occurs in bronchiolitis obliterans syndrome after human lung transplantation.** *American journal of transplantation*
Kelly, F. L., KENNEDY, V. E., Jain, R., Sindhwani, N. S., Finlen Copeland, C. A., Snyder, L. D., Eu, J. P., Meltzer, E. B., Brockway, B. L., Pavlisko, E., Stripp, B. R., Palmer, S. M.
2012; 12 (11): 3076-3084